Isenhour Cheryl J, Skoff Tami H, Lindley Megan C, Zhou Fangjun, Hariri Susan
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
AJPM Focus. 2022 Dec 22;2(1):100060. doi: 10.1016/j.focus.2022.100060. eCollection 2023 Mar.
Vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during pregnancy is highly effective against in young infants. We aimed to evaluate the uptake of maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination during the recommended gestation period of 27 through 36 weeks among women enrolled in a public medical insurance plan in the U.S.
In this analysis using Centers for Medicare and Medicaid Services insurance claims data, we identified women aged 15 through 49 years who delivered a live-born infant from 2016 through 2019. We identified claims for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination to calculate the proportion of women who were vaccinated during Weeks 27 through 36 of gestation in each calendar year. We also assessed the average annual maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis coverage by age group, race and ethnicity, U.S. Census region of residence, and plan type. Data were analyzed in 2021.
Among 4,318,823 deliveries, the 4-year national average for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination was 26%, improving from 22% in 2016 to 31% in 2019 (<0.001). Within subgroups, the lowest 4-year average coverage was among women aged 15 through 18 years (22%); Black, non-Hispanic (23%) and Hispanic women (24%); those residing in the South (18%); those enrolled in a Children's Health Insurance Program plan (22%); and those covered by a fee-for-service plan (19%). Coverage increased across all subgroups from 2016 through 2019.
Although maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis coverage among publicly insured women in the U.S. increased from 2016 through 2019, it remained considerably lower than estimated national coverage, with notable differences by race and ethnicity.
孕期接种破伤风类毒素、白喉类毒素减少和无细胞百日咳疫苗对预防幼儿感染非常有效。我们旨在评估美国参加公共医疗保险计划的女性在推荐的孕期27至36周内接种破伤风类毒素、白喉类毒素减少和无细胞百日咳疫苗的情况。
在这项使用医疗保险和医疗补助服务中心保险理赔数据的分析中,我们确定了2016年至2019年期间分娩活产婴儿的15至49岁女性。我们确定了破伤风类毒素、白喉类毒素减少和无细胞百日咳疫苗接种的理赔记录,以计算每个日历年中在孕期第27至36周接种疫苗的女性比例。我们还按年龄组、种族和族裔、美国人口普查居住地区和计划类型评估了每年孕妇破伤风类毒素、白喉类毒素减少和无细胞百日咳疫苗的平均接种覆盖率。数据于2021年进行分析。
在4318823例分娩中,4年全国破伤风类毒素、白喉类毒素减少和无细胞百日咳疫苗接种的平均比例为26%,从2016年的22%提高到2019年的31%(<0.001)。在亚组中,4年平均覆盖率最低的是15至18岁的女性(22%);黑人、非西班牙裔(23%)和西班牙裔女性(24%);居住在南部的女性(18%);参加儿童健康保险计划的女性(22%);以及参加按服务收费计划的女性(19%)。从2016年到2019年,所有亚组的覆盖率都有所提高。
尽管2016年至2019年期间美国参加公共保险的女性中破伤风类毒素、白喉类毒素减少和无细胞百日咳疫苗的接种覆盖率有所提高,但仍远低于估计的全国覆盖率,不同种族和族裔之间存在显著差异。